Does the media prefer IOVA or QGEN?

In the previous week, Iovance Biotherapeutics had 2 more articles in the media than Qiagen. MarketBeat recorded 17 mentions for Iovance Biotherapeutics and 15 mentions for Qiagen. Iovance Biotherapeutics' average media sentiment score of 0.35 beat Qiagen's score of -0.52 indicating that Iovance Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Qiagen 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Does the media prefer IMVT or IOVA?

In the previous week, Iovance Biotherapeutics had 8 more articles in the media than Immunovant. MarketBeat recorded 17 mentions for Iovance Biotherapeutics and 9 mentions for Immunovant. Immunovant's average media sentiment score of 0.55 beat Iovance Biotherapeutics' score of 0.35 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Iovance Biotherapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor IOVA or PCVX?

In the previous week, Iovance Biotherapeutics had 13 more articles in the media than Vaxcyte. MarketBeat recorded 17 mentions for Iovance Biotherapeutics and 4 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.47 beat Iovance Biotherapeutics' score of 0.35 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vaxcyte 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to LNTH or IOVA?

In the previous week, Iovance Biotherapeutics had 13 more articles in the media than Lantheus. MarketBeat recorded 17 mentions for Iovance Biotherapeutics and 4 mentions for Lantheus. Lantheus' average media sentiment score of 0.57 beat Iovance Biotherapeutics' score of 0.35 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Iovance Biotherapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer IOVA or KYMR?

In the previous week, Iovance Biotherapeutics had 8 more articles in the media than Kymera Therapeutics. MarketBeat recorded 17 mentions for Iovance Biotherapeutics and 9 mentions for Kymera Therapeutics. Iovance Biotherapeutics' average media sentiment score of 0.35 beat Kymera Therapeutics' score of 0.33 indicating that Iovance Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kymera Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Iovance Biotherapeutics (IOVA) Competitors

$4.10 0.00 (0.00%)

Closing price 05/29/2026 04:00 PM Eastern

Extended Trading

$4.05 -0.05 (-1.22%)

As of 07:49 AM Eastern

Compare

IOVA vs. QGEN, IMVT, PCVX, LNTH, and KYMR

Should you buy Iovance Biotherapeutics stock or one of its competitors? MarketBeat compares Iovance Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Iovance Biotherapeutics include Qiagen (QGEN), Immunovant (IMVT), Vaxcyte (PCVX), Lantheus (LNTH), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry.

How does Iovance Biotherapeutics compare to Qiagen?

Iovance Biotherapeutics (NASDAQ:IOVA) and Qiagen (NYSE:QGEN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

Qiagen has higher revenue and earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	6.95	-$390.98M	-$0.95	N/A
Qiagen	$2.09B	3.61	$424.88M	$1.91	19.17

Iovance Biotherapeutics has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market. Comparatively, Qiagen has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

Iovance Biotherapeutics currently has a consensus price target of $8.43, suggesting a potential upside of 105.57%. Qiagen has a consensus price target of $44.98, suggesting a potential upside of 22.83%. Given Iovance Biotherapeutics' higher possible upside, equities analysts clearly believe Iovance Biotherapeutics is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
Qiagen	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42

Qiagen has a net margin of 19.16% compared to Iovance Biotherapeutics' net margin of -123.92%. Qiagen's return on equity of 14.40% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%
Qiagen	19.16%	14.40%	8.40%

77.0% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 7.8% of Iovance Biotherapeutics shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Iovance Biotherapeutics had 2 more articles in the media than Qiagen. MarketBeat recorded 17 mentions for Iovance Biotherapeutics and 15 mentions for Qiagen. Iovance Biotherapeutics' average media sentiment score of 0.35 beat Qiagen's score of -0.52 indicating that Iovance Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Qiagen	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

Qiagen beats Iovance Biotherapeutics on 10 of the 17 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Immunovant has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -123.92%. Iovance Biotherapeutics' return on equity of -50.17% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%

Iovance Biotherapeutics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Iovance Biotherapeutics	$263.50M	6.95	-$390.98M	-$0.95	N/A

47.1% of Immunovant shares are held by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are held by institutional investors. 1.8% of Immunovant shares are held by company insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Iovance Biotherapeutics had 8 more articles in the media than Immunovant. MarketBeat recorded 17 mentions for Iovance Biotherapeutics and 9 mentions for Immunovant. Immunovant's average media sentiment score of 0.55 beat Iovance Biotherapeutics' score of 0.35 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Iovance Biotherapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunovant currently has a consensus price target of $37.33, indicating a potential upside of 12.11%. Iovance Biotherapeutics has a consensus price target of $8.43, indicating a potential upside of 105.57%. Given Iovance Biotherapeutics' higher possible upside, analysts plainly believe Iovance Biotherapeutics is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30

Immunovant has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market.

Summary

Iovance Biotherapeutics beats Immunovant on 10 of the 15 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to Vaxcyte?

Iovance Biotherapeutics (NASDAQ:IOVA) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Iovance Biotherapeutics has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market.

Iovance Biotherapeutics has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	6.95	-$390.98M	-$0.95	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

Vaxcyte has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -123.92%. Vaxcyte's return on equity of -32.51% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%
Vaxcyte	N/A	-32.51%	-29.51%

Iovance Biotherapeutics currently has a consensus target price of $8.43, suggesting a potential upside of 105.57%. Vaxcyte has a consensus target price of $86.00, suggesting a potential upside of 67.32%. Given Iovance Biotherapeutics' higher probable upside, analysts plainly believe Iovance Biotherapeutics is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Iovance Biotherapeutics had 13 more articles in the media than Vaxcyte. MarketBeat recorded 17 mentions for Iovance Biotherapeutics and 4 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.47 beat Iovance Biotherapeutics' score of 0.35 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vaxcyte	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

77.0% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 7.8% of Iovance Biotherapeutics shares are held by company insiders. Comparatively, 3.3% of Vaxcyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Vaxcyte beats Iovance Biotherapeutics on 8 of the 15 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

In the previous week, Iovance Biotherapeutics had 13 more articles in the media than Lantheus. MarketBeat recorded 17 mentions for Iovance Biotherapeutics and 4 mentions for Lantheus. Lantheus' average media sentiment score of 0.57 beat Iovance Biotherapeutics' score of 0.35 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Iovance Biotherapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lantheus has higher revenue and earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.19	$233.56M	$4.15	23.93
Iovance Biotherapeutics	$263.50M	6.95	-$390.98M	-$0.95	N/A

Lantheus presently has a consensus target price of $101.86, indicating a potential upside of 2.58%. Iovance Biotherapeutics has a consensus target price of $8.43, indicating a potential upside of 105.57%. Given Iovance Biotherapeutics' higher probable upside, analysts clearly believe Iovance Biotherapeutics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30

Lantheus has a net margin of 18.05% compared to Iovance Biotherapeutics' net margin of -123.92%. Lantheus' return on equity of 29.32% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 1.7% of Lantheus shares are owned by company insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Lantheus has a beta of -0.03, suggesting that its share price is 103% less volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market.

Summary

Lantheus beats Iovance Biotherapeutics on 11 of the 16 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to Kymera Therapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Iovance Biotherapeutics has a net margin of -123.92% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 7.8% of Iovance Biotherapeutics shares are owned by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Iovance Biotherapeutics currently has a consensus target price of $8.43, suggesting a potential upside of 105.57%. Kymera Therapeutics has a consensus target price of $118.10, suggesting a potential upside of 45.04%. Given Iovance Biotherapeutics' higher probable upside, research analysts clearly believe Iovance Biotherapeutics is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.95

In the previous week, Iovance Biotherapeutics had 8 more articles in the media than Kymera Therapeutics. MarketBeat recorded 17 mentions for Iovance Biotherapeutics and 9 mentions for Kymera Therapeutics. Iovance Biotherapeutics' average media sentiment score of 0.35 beat Kymera Therapeutics' score of 0.33 indicating that Iovance Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kymera Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kymera Therapeutics has lower revenue, but higher earnings than Iovance Biotherapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	6.95	-$390.98M	-$0.95	N/A
Kymera Therapeutics	$39.21M	170.81	-$311.35M	-$3.57	N/A

Iovance Biotherapeutics has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.02, indicating that its stock price is 102% more volatile than the broader market.

Summary

Kymera Therapeutics beats Iovance Biotherapeutics on 9 of the 17 factors compared between the two stocks.

Get Iovance Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IOVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IOVA vs. The Competition

Export

Metric	Iovance Biotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.83B	$3.40B	$6.40B	$12.57B
Dividend Yield	N/A	2.29%	2.68%	5.31%
P/E Ratio	-4.32	18.88	21.37	26.27
Price / Sales	6.95	334.85	558.97	114.93
Price / Cash	N/A	54.19	27.44	37.60
Price / Book	2.33	6.93	10.08	6.86
Net Income	-$390.98M	$24.20M	$3.56B	$337.26M
7 Day Performance	-0.24%	4.02%	2.83%	3.53%
1 Month Performance	N/A	N/A	N/A	-0.79%
1 Year Performance	134.02%	65.97%	37.60%	39.66%

Iovance Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IOVA Iovance Biotherapeutics	3.1232 of 5 stars	$4.10 flat	$8.43 +105.6%	+134.0%	$1.83B	$263.50M	N/A	500	Trending News Analyst Revision Gap Up
QGEN Qiagen	4.1689 of 5 stars	$35.23 +0.2%	$44.98 +27.7%	-22.9%	$7.26B	$2.09B	18.40	5,654	Trending News Analyst Downgrade
IMVT Immunovant	1.9763 of 5 stars	$34.15 flat	$35.33 +3.5%	+123.9%	$7.01B	N/A	N/A	120	Insider Trade
PCVX Vaxcyte	2.827 of 5 stars	$47.30 flat	$86.00 +81.8%	+57.7%	$6.83B	N/A	N/A	160
LNTH Lantheus	2.2417 of 5 stars	$103.00 flat	$99.71 -3.2%	+31.5%	$6.71B	$1.54B	24.82	1,193	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IOVA) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Iovance Biotherapeutics (IOVA) Competitors

IOVA vs. QGEN, IMVT, PCVX, LNTH, and KYMR

How does Iovance Biotherapeutics compare to Qiagen?

Summary

How does Iovance Biotherapeutics compare to Immunovant?

Summary

How does Iovance Biotherapeutics compare to Vaxcyte?

Summary

How does Iovance Biotherapeutics compare to Lantheus?

Summary

How does Iovance Biotherapeutics compare to Kymera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOVA vs. The Competition

Iovance Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Iovance Biotherapeutics (IOVA) Competitors

IOVA vs. QGEN, IMVT, PCVX, LNTH, and KYMR

How does Iovance Biotherapeutics compare to Qiagen?

Which has preferable earnings & valuation, IOVA or QGEN?

Which has more risk and volatility, IOVA or QGEN?

Do analysts rate IOVA or QGEN?

Is IOVA or QGEN more profitable?

Do insiders & institutionals hold more shares of IOVA or QGEN?

Does the media prefer IOVA or QGEN?

Summary

How does Iovance Biotherapeutics compare to Immunovant?

Is IMVT or IOVA more profitable?

Which has stronger valuation & earnings, IMVT or IOVA?

Do institutionals & insiders believe in IMVT or IOVA?

Does the media prefer IMVT or IOVA?

Do analysts prefer IMVT or IOVA?

Which has more risk and volatility, IMVT or IOVA?

Summary

How does Iovance Biotherapeutics compare to Vaxcyte?

Which has more volatility and risk, IOVA or PCVX?

Which has higher valuation and earnings, IOVA or PCVX?

Is IOVA or PCVX more profitable?

Do analysts prefer IOVA or PCVX?

Does the media favor IOVA or PCVX?

Do insiders & institutionals have more ownership in IOVA or PCVX?

Summary

How does Iovance Biotherapeutics compare to Lantheus?

Does the media refer more to LNTH or IOVA?

Which has higher earnings & valuation, LNTH or IOVA?

Do analysts rate LNTH or IOVA?

Is LNTH or IOVA more profitable?

Do institutionals & insiders believe in LNTH or IOVA?

Which has more risk and volatility, LNTH or IOVA?

Summary

How does Iovance Biotherapeutics compare to Kymera Therapeutics?

Is IOVA or KYMR more profitable?

Do insiders and institutionals hold more shares of IOVA or KYMR?

Do analysts prefer IOVA or KYMR?

Does the media prefer IOVA or KYMR?

Which has stronger earnings and valuation, IOVA or KYMR?

Which has more risk and volatility, IOVA or KYMR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOVA vs. The Competition

Iovance Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools